News

GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...
Pharmaceuticals and Biotechnology Co-development Agreements Analysis Report 2025 with Directory of Deals Signed Since 2016
The "Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing of co-development deals ...